AMDL proceeds with Chinese acqusitions
AMDL, a US developer and marketer of tests for the early detection of cancer and other serious diseases, says that it is continuing due diligence with Jade Capital Group for the acquisition of Jiangxi Jade Biochemistry Pharmacy and Yangbian Yiqiao Biochemistry Pharmacy previously announced last November. Financial statements are being completed.
"The company is also continuing to gather data requested by the US Food and Drug Administration following our last review. AMDL's primary objective remains receiving FDA clearance to market our DR-70 test in the USA. FDA clearance to market would simultaneously increase market awareness and acceptance in international markets," said Gary Dreher, chief executive of AMDL.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze